141 related articles for article (PubMed ID: 15154373)
1. [Immunohistochemical study of the prostate-specific antigen in prostatic cancer].
Karseladze AI; Rytin IIe; Budunova IV
Arkh Patol; 2004; 66(2):3-7. PubMed ID: 15154373
[TBL] [Abstract][Full Text] [Related]
2. [Alpha2-macroglobulin in various pathological conditions of the prostate].
Karseladze AI; Rytin IE; Kulevich EE
Arkh Patol; 2005; 67(1):33-6. PubMed ID: 15822792
[TBL] [Abstract][Full Text] [Related]
3. [Prostatic cancer: immunochemical control over chemotherapy].
Nikolaev AA; Lutskiĭ DL; Nikolaeva NN
Urologiia; 2000; (3):41-3. PubMed ID: 11186710
[TBL] [Abstract][Full Text] [Related]
4. [Summary of our clinical experience with the determination of serum prostate-specific antigen level in the first five years].
Bánfi G; Kiss F; Kádár A; Romics I
Magy Onkol; 2003; 47(2):165-8. PubMed ID: 12975664
[TBL] [Abstract][Full Text] [Related]
5. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
6. Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma.
Mai KT; Yazdi HM; Farmer J
Prostate; 2001 May; 47(3):172-82. PubMed ID: 11351346
[TBL] [Abstract][Full Text] [Related]
7. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
Elkord E; Rowbottom AW; Kynaston H; Williams PE
Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine differentiation and markers of cell proliferation in a group of patients with prostate adenocarcinoma and normal or high serum prostate-specific antigen levels].
Feria-Bernal G; García-Gonzalez VM; Figueroa-Granados V; Martinez-Benítez B; Uribe-Uribe NO
Gac Med Mex; 2006; 142(6):441-6. PubMed ID: 17201105
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse.
Sakko AJ; Butler MS; Byers S; Reinboth BJ; Stahl J; Kench JG; Horvath LG; Sutherland RL; Stricker PD; Henshall SM; Marshall VR; Tilley WD; Horsfall DJ; Ricciardelli C
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2488-97. PubMed ID: 18768520
[TBL] [Abstract][Full Text] [Related]
10. Correlation of serum prostate specific antigen and quantitative immunohistochemistry.
Weir EG; Partin AW; Epstein JI
J Urol; 2000 Jun; 163(6):1739-42. PubMed ID: 10799172
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
13. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
[TBL] [Abstract][Full Text] [Related]
14. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
15. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
18. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
19. Morphological features correlation with serum tumour markers in prostatic carcinoma.
Afzal S; Ahmad M; Mushtaq S; Mubarik A; Qureshi AH; Khan SA
J Coll Physicians Surg Pak; 2003 Sep; 13(9):511-4. PubMed ID: 12971871
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
Rydén L; Egevad L; Ekman P; Hellström M
Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
